SanMiguel J; Facon T; Cavo M., Recent phase III trials in the frontline treatment of multiple myeloma: evaluating their impact on community practice., «CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY», 2008, 6, pp. s4 - s10 [Scientific article]
CAVO M; ATTAL M; GERTZ MA; GIRALT S; LUDWIG H; MORGAN GJ; ANDERSON KC., The current landscape of multiple myeloma treatment, «LEUKEMIA RESEARCH», 2008, 32, pp. S1 - S2 [Scientific article]
Hussein M.A.;Vrionis F.D.;Allison R.;Berenson J.;Berven S.;Erdem E.;Giralt S.;Jagannath S.;Kyle R.A.;LeGrand S.;Pflugmacher R.;Raje N.;Rajkumar S.V.;Randall R.L.;Roodman D.;Siegel D.;Vescio R.;Zonder J.;Durie B.G.;International Myeloma Working Group [..; Cavo M; ..], The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement., «LEUKEMIA», 2008, 22, pp. 1479 - 1484 [Scientific article]
Nanni C; Rubello D; Zamagni E; Castellucci P; Ambrosini V; Montini G; Cavo M; Lodi F; Pettinato C; Grassetto G; Franchi R; Gross MD; Fanti S., 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone., «IN VIVO», 2008, 22, pp. 513 - 517 [Scientific article]
Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M., A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma., «HAEMATOLOGICA», 2007, 92(1), pp. 50 - 55 [Scientific article]
Cavo M, Current status of bortezomib in the treatment of multiple myeloma., «CURRENT HEMATOLOGIC MALIGNANCY REPORTS», 2007, 2, pp. 128 - 137 [Scientific article]
C. Terragna; M. Renzulli; D. Remondini; E. Tagliafico; E. Roncaglia; P. Tosi; E. Zamagni; P. Tacchetti; G. Perrone; M. Ceccolini; G. Martinelli; M. Baccarani; M. Cavo, Gene expression profiling (gep) of myeloma (MM) cells to predict attainment near complete response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed MM, in: , «BLOOD», 2007, 108(atti di: 48th American Society for Hematology Annual Meeting, Orlando, Florida, December 9-12, 2006) [Abstract]
Cavo M., Le gammapatie monoclonali., in: TURA S., Corso di Malattie del Sangue e degli Organi Emolinfopoietici., BOLOGNA, Esculapio, 2007, pp. 262 - 287 [Chapter or essay]
Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA., Neuropathy in multiple myeloma treated with thalidomide: a prospective study., «NEUROLOGY», 2007, 69, pp. 573 - 581 [Scientific article]
Cavo M., Nonmyeloablative allotransplantation for myeloma: light and shade., «BLOOD», 2007, 109, pp. 3134 - 3135 [Scientific article]
Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM., Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides., «BRITISH JOURNAL OF HAEMATOLOGY», 2007, 139, pp. 415 - 424 [Scientific article]
Terragna C.; Renzulli M.; Remondini D.; Tagliafico E.; Roncaglia E.; Tosi P.; Zamagni E.; Tacchetti P.; Perrone G.; Ceccolini M.; Brioli AM.; Martinelli G.; Baccarani M.; Cavo M., Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep), in: , «HAEMATOLOGICA», 2007, 92(s2)(atti di: 12th Congress of the European Hematology Association, Vienna, Austria, June 7-10, 2007) [Abstract]
Terragna, Carolina; Renzulli, Matteo; Remondini, Daniel; Tagliafico, E.; Roncaglia, E.; Tosi, Patrizia; Zamagni, Elena; Tacchetti, Paola; Perrone, Giulia; Ceccolini, Michela; Brioli, A. m.; Martinelli, Giovanni; Baccarani, Michele; Cavo, Michele, Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep), in: Haematologica, Vienna, Austria, 2007, 92(s2), pp. 92 - 92 (atti di: 12th Congress of the European Hematology Association, Vienna, Austria, June 7-10, 2007) [Abstract]
Zamagni E.; Valdrè L.; Palareti G.; Cavo M., Prevention of VTE in multiple myeloma patients., «THROMBOSIS RESEARCH», 2007, 120 suppl 2, pp. S133 - S136 [Scientific article]
Cavo M; Tosi P; Zamagni E; Cellini C; Tacchetti P; Patriarca F; Di Raimondo F; Volpe E; Ronconi S; Cangini D; Narni F; Carubelli A; Masini L; Catalano L; Fiacchini M; de Vivo A; Gozzetti A; Lazzaro A; Tura S; Baccarani M., Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study., «JOURNAL OF CLINICAL ONCOLOGY», 2007, 25, pp. 2434 - 2441 [Scientific article]
